0.20
+3.51%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Context Therapeutics
From its filings with the US Securities and Exchange Commission
Context Therapeutics is based in Philadelphia, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CNTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $36.1m. At that date it held total assets of $68.5m and shareholders' equity of $60.5m.
We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (“CLDN6”) x CD3 TCE, CT-95, a Mesothelin (“MSLN”) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (“Nectin-4”) x CD3 TCE.
CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. IND-enabling studies on CTIM-76 have been completed. On May 2, 2024, we announced the U.S. Food and Drug Administration (the “FDA”) cleared our IND application to support the initiation of a Phase 1 dose escalation and expansion trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. We dosed the first patient in our CTIM-76 Phase 1 trial in January 2025. We expect to share Phase 1a interim data for the CTIM-76 trial in June 2026.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Oct 2021
- Employees
- 15
- Website
- contexttherapeutics.com ↗
- Head office
- 2001 MARKET STREET, PHILADELPHIA, PA, 19103
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Andy PasternakIndependent Chairman of the Board
- Mr. Martin LehrPresident, Chief Executive Officer, Director, since 2015$1.0m
- Ms. Jennifer Minai-AzaryChief Financial Officer, Treasurer$698,968
- Dr. Karen ChaginChief Medical Officer
- Mr. Alex LevitChief Legal Officer and Corporate Secretary$670,653
- Dr. Philip KantoffIndependent Director$81,819
- Dr. Karen SmithIndependent Director$50,890
- Ms. Jennifer StaceyIndependent Director$96,702
- Dr. Luke WalkerIndependent Director$50,405
- Ms. Linda WestIndependent Director$100,687
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinical-stage biopharmaceutical company focused on women with cancer in Philadelphia.
- Developing CTIM-76, a selective Claudin 6 x CD3 bispecific antibody for CLDN6-positive tumors.
- Preclinical program CTIM-76 targets ovarian, lung, and testicular tumors with low healthy tissue expression.
Weaknesses
- Only 9 full-time employees in a clinical-stage biopharmaceutical company.
- IPO listed on 20 October 2021 with limited market presence.
- Small team size of 15 employees may hinder rapid development.
Opportunities
- Expanding CTIM-76 to target ovarian, lung, and testicular tumors in clinical trials.
- Growing market for CLDN6-positive tumor treatments in Health Care sector.
- Potential for CTIM-76 to address unmet needs in women's cancer care.
Threats
- Competition from other biopharmaceutical companies in the Health Care sector.
- Regulatory challenges in developing bispecific antibodies for cancer treatment.
- Limited funding due to small company size and recent IPO.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.